MediciNova (MNOV) Leaps on FDA Nod

MediciNova, Inc MNOV shares climbed 46.2% to $5.13 after the company reported the FDA approval of the second Phase 2 protocol for MN-001 in NASH which targets NASH patients with hypertriglyceridemia. Share volume was 355,000, compared to an all-day average of 8,100
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!